toreig.blogg.se

COVID-19-related symptoms included, among others, fatigue, cough, chest tightness, dyspnea, headache, fever, altered smell or taste, myalgias, gastrointestinal symptoms (such as nausea, vomiting, or diarrhea), sleep disturbance, and limitations with activities of daily living. PASC or long COVID-19 was defined as the persistence of COVID-19-related symptoms beyond 30 days of diagnosis or the emergence of new COVID19-related symptoms reported during a hospital or clinic encounter throughout the follow-up period that extended up to 14 months. Re-admissions were classified as either related or non-related to COVID-19 based on the reason for hospitalization as well as the reported signs and symptoms. Chart reviews were conducted for each patient’s encounter that included visits to our acute cancer care center, hospital re-admission, or clinic visit. Patient questionnaires were sent out remotely daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then monthly thereafter. Patients were followed from March 2020 until May 31, 2021. We followed these patients as longitudinal cohort through patient-reported outcomes (PRO)-based remote symptom monitoring along with usual care with clinician visits. None of the patients were vaccinated during the period of initial COVID diagnosis. We identified patients with cancer receiving care at the University of Texas MD Anderson Cancer Center who were also diagnosed with COVID-19 disease between March 1, 2020, and September 1, 2020. Since cancer patients fall in a higher COVID-19 risk group ( Dai et al., 2020) and in order to provide a better understanding of post-COVID-19 management among cancer patients, we sought to characterize the patterns of long COVID-19 in the specific cancer patient population. Several studies suggest the persistence of symptoms past 30 days in patients with severe initial COVID-19 symptoms and those that were hospitalized due to COVID-19 ( Barman et al., 2020 Carfì et al., 2020 Halpin et al., 2021), while other studies have shown a prevalence of PASC among COVID-19 outpatients as well ( Xiong et al., 2021 Goërtz et al., 2020 Tenforde et al., 2020b).

The reported prevalence of PASC widely varies from 10% up to 87% in the general population ( Nalbandian et al., 2021 Xiong et al., 2021 Goërtz et al., 2020 Bowles et al., 2021 Carfì et al., 2020 Halpin et al., 2021) and there is limited data available on PASC in cancer patients and how it affects their cancer progression, care, and treatment. The long-term consequences of COVID-19 remain to be fully understood and there is no unequivocal consensus on the definition of post-acute sequelae of SARS-CoV-2 infection (PASC), with one adopted definition being the persistence of symptoms or new delayed complications that develop at least 4 weeks after a COVID-19 diagnosis ( Nalbandian et al., 2021 Datta et al., 2020 Greenhalgh et al., 2020). The earliest studies characterized the acute and sub-acute effects of COVID-19 on multiple organ systems ( Gupta et al., 2020) while more recent work has raised concern on the chronic symptoms attributed to COVID-19 that persist beyond the expected recovery period ( Barman et al., 2020 Nalbandian et al., 2021) with some symptoms similar to those experienced during the recovery of other viral illnesses ( Xiong et al., 2021 Goërtz et al., 2020 Ahmed et al., 2020 Hui et al., 2005 Kausler et al., 1986 Moldofsky and Patcai, 2011).

Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, United States Ĭlinical outcomes of COVID-19 in patients with cancer remains an area of active study with several studies showing more severe outcomes and associated risk factors such as pre-existing comorbidities, cancer stage and therapy, and immunocompromised state, compared to the non-cancer population ( Dai et al., 2020 Petrilli et al., 2020 Wu and McGoogan, 2020 Zhou et al., 2020).Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, United States.Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, United States.Gastroenterology Research, The University of Texas MD Anderson Cancer Center, United States.Emergency Medicine-Research, The University of Texas MD Anderson Cancer Center, United States.Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, United States.Hospital Medicine, The University of Texas MD Anderson Cancer Center, United States.

Integrative Medicine Program, The University of Texas MD Anderson Cancer Center, United States.Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, United States.